X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zynlonta (loncastuximab tesirine) is a CD19-directed antibody drug conjugate, which is being evaluated in combination with glofitamab & obinutuzumab for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Lead Product(s): Loncastuximab Tesirine,Glofitamab,Obinutuzumab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19, is approved by FDA and EU for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Overland Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
ADC Therapeutics' CD19-specific Antibody Drug Conjugate (ADC), Zynlonta (loncastuximab tesirine-lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19, is being developed in combination with rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
ADC Therapeutics' CD19-specific Antibody Drug Conjugate (ADC), Zynlonta (loncastuximab tesirine-lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: IntoCell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2023
Details:
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC), Loncastuximab Tesirine-lpyl. Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum (also called RenMiceTM HiTS Platform).
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Biocytogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 27, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The opinion is based on data from LOTIS-2, a large (n=145) Phase 2 multinational, single-arm clinical trial of ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory DLBCL following two or more prior lines of systemic therapy.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
The financing will enable and support to continue maximizing the potential of ZYNLONTA and advancing the pipeline of novel antibody drug conjugates for hematologic malignancies and solid tumors.
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Owl Rock
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
